https://www.nasdaq.com/press-release/axcella-therapeutics-to-present-at-the-h.c.-wainwright-bioconnect-conference-2022-01
https://www.nasdaq.com/press-release/axcella-therapeutics-announces-initiation-of-axa1125-long-covid-phase-2a-clinical
https://www.nasdaq.com/press-release/axcella-therapeutics-promotes-margaret-koziel-m.d.-to-chief-medical-officer-2021-12
https://www.nasdaq.com/press-release/axcella-therapeutics-to-participate-in-piper-sandler-33rd-annual-healthcare
https://www.nasdaq.com/press-release/axcella-therapeutics-reports-third-quarter-financial-results-and-provides-update-on
https://www.nasdaq.com/press-release/axcella-therapeutics-announces-upcoming-presentations-at-aaslds-the-liver-meetingr
https://www.nasdaq.com/press-release/axcella-therapeutics-launches-clinical-program-to-develop-treatment-for-patients-with
https://www.nasdaq.com/press-release/axcella-now-axcella-therapeutics-to-host-virtual-rd-day-on-october-26-2021-2021-10-19
https://www.nasdaq.com/press-release/invaio-sciences-secures-%2450-million-debt-financing-to-develop-and-commercialize-0
https://www.nasdaq.com/press-release/axcella-announces-upcoming-investor-conference-presentation-2021-10-05
https://www.nasdaq.com/press-release/axcella-announces-upcoming-investor-conference-presentation-2021-09-07
https://www.nasdaq.com/press-release/axcella-announces-publication-in-the-american-journal-of-gastroenterology-of-positive
https://www.nasdaq.com/press-release/axcella-reports-second-quarter-financial-results-and-provides-business-update-2021-07
https://www.nasdaq.com/press-release/axcella-to-report-second-quarter-2021-financial-results-on-july-29-2021-2021-07-22
https://www.nasdaq.com/press-release/axcella-announces-initiation-of-emmpowersm-phase-2-clinical-trial-of-axa1665-2021-06
https://www.nasdaq.com/press-release/invaio-sciences-raises-%2488.9-million-to-accelerate-the-transition-to-biological
https://www.nasdaq.com/press-release/positive-clinical-data-about-axcellas-axa1665-candidate-for-overt-hepatic
https://www.nasdaq.com/press-release/invaio-sciences-announces-key-agreement-with-fundecitrus-in-brazil-to-combat-against
https://www.nasdaq.com/press-release/axcella-announces-initiation-of-emmpactsm-phase-2b-clinical-trial-of-axa1125-2021-05
https://www.nasdaq.com/press-release/axcella-reports-first-quarter-financial-results-and-provides-business-update-2021-05
https://www.nasdaq.com/press-release/axcella-to-report-first-quarter-2021-financial-results-on-may-6-2021-2021-04-27
https://www.nasdaq.com/press-release/axcella-announces-upcoming-oral-presentation-at-digestive-disease-week-ddw-2021-2021
https://www.nasdaq.com/press-release/axcella-announces-axa1125s-ind-clearance-for-the-treatment-of-nash-2021-04-13
https://www.nasdaq.com/press-release/invaio-sciences-strengthens-leadership-team-with-appointment-of-peleg-chevion-as
https://www.nasdaq.com/press-release/axcella-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/axcella-to-report-fourth-quarter-and-full-year-2020-financial-results-on-march-17
https://www.nasdaq.com/press-release/axcella-announces-alison-d.-schecter-m.d.-as-president-of-rd-2021-03-03
https://www.nasdaq.com/press-release/axcella-announces-upcoming-presentations-at-nash-tag-2021-2021-02-25
https://www.nasdaq.com/press-release/cellarity-raises-%24123-million-in-series-b-funding-to-pioneer-a-new-approach-to-drug
https://www.nasdaq.com/press-release/axcella-to-present-at-upcoming-investor-conferences-2021-02-18
https://www.nasdaq.com/press-release/axcella-announces-ind-clearance-for-axa1665-program-updates-and-2021-milestones-2021
https://www.nasdaq.com/press-release/axcella-announces-upcoming-presentation-at-j.p.-morgan-healthcare-conference-2021-01
https://www.nasdaq.com/press-release/axcella-announces-upcoming-investor-conference-presentation-2020-11-20
https://www.nasdaq.com/press-release/axcella-presents-data-for-axa1125-at-the-liver-meetingr-2020-2020-11-13
https://www.nasdaq.com/press-release/axcella-reports-third-quarter-2020-financial-results-and-provides-business-update
https://www.nasdaq.com/press-release/axcella-to-report-third-quarter-2020-financial-results-and-hold-conference-call-on
https://www.nasdaq.com/press-release/axcella-announces-upcoming-presentations-at-aaslds-the-liver-meetingr-2020-2020-10-02
https://www.nasdaq.com/press-release/new-publication-highlights-therapeutic-potential-of-endogenous-metabolic-modulators
https://www.nasdaq.com/press-release/axcella-announces-upcoming-investor-conference-presentation-2020-09-29
https://www.nasdaq.com/press-release/company-profile-for-axcella-health-inc.-2020-09-24
https://www.nasdaq.com/press-release/axcella-to-present-at-upcoming-investor-conferences-2020-09-08
https://www.nasdaq.com/press-release/axcellas-late-breaker-data-from-axa1125-003-clinical-study-presented-at-the-easl
https://www.nasdaq.com/press-release/axcella-announces-upcoming-later-breaker-presentation-at-the-digital-international
https://www.nasdaq.com/press-release/results-of-axcellas-axa1665-001-clinical-study-published-in-clinical-and
https://www.nasdaq.com/press-release/correcting-and-replacing-axcella-reports-positive-top-line-data-from-axa1665-002-and
https://www.nasdaq.com/press-release/axcella-to-report-second-quarter-2020-financial-results-and-hold-conference-call-on
https://www.nasdaq.com/press-release/flagship-pioneerings-scientists-invent-a-new-category-of-genome-engineering
https://www.nasdaq.com/press-release/axcella-reports-first-quarter-financial-results-and-provides-business-update-2020-05
https://www.nasdaq.com/press-release/axcella-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides
https://www.nasdaq.com/press-release/axcella-presents-data-at-ash-annual-meeting-2019-12-07
https://www.nasdaq.com/press-release/axcella-strengthens-executive-team-with-key-addition-and-promotion-2019-11-25
https://www.nasdaq.com/press-release/axcella-announces-issuance-of-broad-patent-covering-emm-compositions-2019-11-20
https://www.nasdaq.com/press-release/axcella-health-reports-third-quarter-2019-financial-results-and-provides-company
https://www.nasdaq.com/press-release/axcella-presents-data-at-the-liver-meetingtm-providing-new-mechanistic-insights-on
https://www.nasdaq.com/press-release/axcella-achieves-initial-milestones-with-its-hematology-product-candidate-axa4010
https://www.nasdaq.com/press-release/axcella-enters-into-collaboration-with-cytoo-to-explore-impact-of-dysregulated
